← Leaderboards
Christine Delorenzo
New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc
$14,054,341
Attributed
$16,711,127
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,711,127 · 7
By mechanism
R01$11,302,915 · 4
RF1$4,279,020 · 1
K01$690,567 · 1
R21$438,625 · 1
Top collaborators
- Ramin V Parsey11 shared
- Lee M Ritterband1 shared
Most similar at New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc
Same institution · by research overlap
- Benjamin A Samuels$3,665,187
- Patrick J Brown$2,828,573
- Christoph Kellendonk$13,400,905
- Bret R Rutherford$14,573,720
- Rene Hen$23,960,227
Others in their field
Top investigators on “Functional Disorder”
- Randall J Bateman · Washington University$164,791,794
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- David Heimbrook · Leidos Biomedical Research, Inc.$127,725,513
- Ed Lein · Allen Institute$92,850,604
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- John M Lachin · George Washington University$85,958,868
Research focus
Functional DisorderPositron-Emission TomographyMajor Depressive DisorderMental DepressionIn VivoDepressed MoodChronicAftercareAffectBrainReportingRodentResponseParticipantInsightImageAntidepressive AgentsPharmaceutical PreparationsTracerCohortEnrollmentMolecularDensitySeverities
Grant awards (25)
Mechanistic clinical trial evaluating the role of the metabotropic glutamate receptor subtype 5 (mGluR5) in the antidepressant mechanism of Cognitive Behavioral Therapy for Insomnia (CBT-I)$808,417
R01 · FY2025 · MH · contact PI
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention$696,610
R01 · FY2024 · MH
Preliminary imaging studies evaluating the vesicular acetylcholine transporter as a treatment target in major depressive disorder$438,625
R21 · FY2024 · MH
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention$70,608
R01 · FY2024 · MH
Role of the metabotropic glutamate receptor subtype 5 in circadian rhythmmisalignment and depression: Implications for treatment$752,564
R01 · FY2023 · MH · contact PI
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention$699,730
R01 · FY2023 · MH
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention - Diversity Administrative supplement for Kimberly Nnah$70,608
R01 · FY2023 · MH
Role of the metabotropic glutamate receptor subtype 5 in circadian rhythmmisalignment and depression: Implications for treatment$752,564
R01 · FY2022 · MH · contact PI
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention$689,078
R01 · FY2022 · MH
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention$49,340
R01 · FY2022 · MH
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention$762,135
R01 · FY2021 · MH
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention$21,899
R01 · FY2021 · MH
Role of the metabotropic glutamate receptor subtype 5 in circadian rhythmmisalignment and depression: Implications for treatment$752,564
R01 · FY2020 · MH · contact PI
A translational study of neuroinflammatory depression: Understanding mechanism and evaluation of a novel pharmacologic intervention$737,050
R01 · FY2020 · MH
Assessing cholinergic circuits and spatial memory loss: a translational study of Alzheimer's disease and a model of cognitive decline$4,279,020
RF1 · FY2019 · AG · contact PI
Role of the metabotropic glutamate receptor subtype 5 in circadian rhythm misalignment and depression: Implications for treatment$752,564
R01 · FY2019 · MH · contact PI
Role of the metabotropic glutamate receptor subtype 5 in circadian rhythm misalignment and depression: Implications for treatment$791,878
R01 · FY2018 · MH · contact PI
Advancing Personalized Antidepressant Treatment Using PET/MRI$702,067
R01 · FY2018 · MH · contact PI
Advancing Personalized Antidepressant Treatment Using PET/MRI$701,782
R01 · FY2017 · MH · contact PI
Advancing Personalized Antidepressant Treatment Using PET/MRI$701,782
R01 · FY2016 · MH · contact PI
Advancing Personalized Antidepressant Treatment Using PET/MRI$789,675
R01 · FY2015 · MH · contact PI
Characterization of a New Metabotropic Glutamate Receptor Subtype 5 PET Ligand$173,191
K01 · FY2014 · MH · contact PI
Characterization of a New Metabotropic Glutamate Receptor Subtype 5 PET Ligand$172,615
K01 · FY2013 · MH · contact PI
Characterization of a New Metabotropic Glutamate Receptor Subtype 5 PET Ligand$171,257
K01 · FY2012 · MH · contact PI
Characterization of a New Metabotropic Glutamate Receptor Subtype 5 PET Ligand$173,504
K01 · FY2011 · MH · contact PI